FINNENCE ▪ THE WIRE FILE
THE WIRE · № 62069
News■ Unclear/unknown
Teva, Samsung Bioepis deepen bonds in pact for up to 6 new biosimilars
KINDNews
DIRECTION■ Unclear/unknown
SOURCES2
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-02 14:00 UTC
LAST UPDATE2026-10-02 14:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A biosimilar partnership expands pipeline breadth, but no financial terms or timelines are disclosed.
Pipeline deal, no near-term financial detail
CATALYST TO WATCH
Regulatory filings and launch timelines
MAIN RISK
Biosimilar development and approval risk
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress2026-10-02 15:00 UTC
BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress2026-10-02 15:00 UTC
→CORRELATIONshares Healthcare
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s2026-10-02 15:13 UTC
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s2026-10-02 15:13 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — Regeneron Pharmaceuticals2026-10-02 12:00 UTC
New Phase 3 trial: Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) — Regeneron Pharmaceuticals2026-10-02 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis — Jiankuan (Suzhou) Biotechnology Company Limited2026-10-02 12:00 UTC
New Phase 3 trial: A Study to Evaluate the Efficacy and Safety of Proximod in Patients With Rheumatoid Arthritis — Jiankuan (Suzhou) Biotechnology Company Limited2026-10-02 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3 trial: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Boehringer Ingelheim2026-10-02 12:00 UTC
New Phase 3 trial: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight — Boehringer Ingelheim2026-10-02 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.